Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients

Antiviral Therapy

Volumn 10, Issue 5, 2005, Pages 605-614

  Ribera, Esteban ^a   Rodríguez Pardo, Dolors ^a   Rubio, Manuel ^b   Soler, Anna ^c   Pedro, Enric ^c   Blanco, José L ^d   González, Alicia ^e   Crespo, Manel ^a   Falcó, Vicenç ^a   Ocaña, Imma ^a   Deig, Elisabeth ^c   Miró, Jose M ^d   Pahissa, Albert ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; VIRUS RNA;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; PILOT PROJECTS; RNA, VIRAL; SPAIN;

EID: 24044520095     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miro JM, Antela A, Gonzalez J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, Lopez-Aldeguer J, Martinez E, Polo R, Tuset M, Viciana P, Santamaria JM, Kindelan JM, Ribera E & Segura F. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enfermedades Infecciosas & Microbiologia Clinica 2004; 22:564-642. Spanish.
2. Kagay CR, Porco TC, Liechty CA, Charlebois E, Clark R, Guzman D, Moss AR & Bangsberg DR. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clinical Infectious Diseases 2004; 38(Suppl 5):S414-S420.
3. Bartlett JA, DeMasi R, Quinn J, Moxham C & Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-1377.
4. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B & Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases 2004; 38:1311-1316.
5. Rosenbach KA, Allison R & Nadler JP. Daily dosing of highly active antiretroviral therapy. Clinical Infectious Diseases 2002; 34:686-692.
6. Frank I. Once-daily HAART: toward a new treatment paradigm. Journal of Acquired Immune Deficiency Syndromes 2002; 31(Suppl 1):S10-S15; discussion S24-S25.
7. Ena J & Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clinical Infectious Diseases 2003; 36:1186-1190.
8. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. International Journal of STD & AIDS 2003; 14(Suppl 1):34-36.
9. Taburet AM, Paci-Bonaventure S, Peytavin G & Molina JM. Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies. Clinical Pharmacokinetics 2003; 42:1179-1191.
10. Garcia F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gomez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miro JM & Gatell JM; Spanish SCAN Study Group. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS 2000; 14:2485-2494.
11. Kunches LM, Reinhalter NE, Marquis A, Coakley E, Cohen C, Morris AB & Mazzullo JM. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. Journal of Acquired Immune Deficiency Syndromes 2001; 28:150-153.
12. De Jesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K & Madison SJ; EPV20001 International Study Team. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naïve adults with HIV infection: a randomised equivalence trial. Clinical Infectious Diseases 2004; 39:411-418.
13. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH & Hoetelmans RM. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14:77-82.
14. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW & Lange JM; 2NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363:1253-1263.
15. Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, Kindelan JM, Carmona A, Juega J & Ocampo A; GEEMA Study Group. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16:605-613.
16. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37:53-72.
17. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, Rizzi L & Suter F; Once Study Group. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Therapy 2001; 6:249-253.
18. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, Kane CT, Delaporte E, Sow PS, Faye MA, Gueye M, Peytavin G, Dalban C, Girard PM & Ndoye I; Imea 011/ANRS 12-04 Study Group. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1-infected adults in Senegal. AIDS 2003; 17:1017-1022.
19. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Arici C, Ravasio L & Suter F. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antiviral Therapy 2003; 8:339-346.
20. Ward D, Cohen C, Keiser P, Morris AB, Sax P, Dezii C, Maa JF, Hodder SL & Tudor JL. Efficacy and safety of efavirenz, lamivudine, didanosine EC as a once-daily regimen for treatment-naive HIV patients: 48-week results from DART I trial. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract TuPeB4594.
21. Lange JM. Efficacy and durability of nevirapine in antiretroviral drug naive patients. Journal of Acquired Immune Deficiency Syndromes 2003; 34(Suppl 1):S40-S52.
22. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM & Chene G. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 2000; 182:599-602.
23. Saag MS, Cahn P, Raffi F, Wolf M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW & Rousseau F; FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial. Journal of the American Medical Association 2004; 292:180-189.
24. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ & Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Journal of the American Medical Association 2004; 292:191-201.
25. Gazzard B, DeJesus E, Campo R, Jemsek J, Galland JE & Arribas JR. The combination of tenofovir, emtricitabine and efavirenz has significantly greater response vs. Combivir and EFV in antiretroviral naïve patients: A 24 week preliminary analysis (study 934). 44th Interscience Conference of Antimicrobial Agents & Chemotherapy. 30 October-2 November 2004, Washington, USA. Abstract H-1137c.
26. De Jesus E, Herrera G, Teofilo E, Gerstoft J, Beltran-Buendía C, Brand D, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER & Scott TR; CNA3 0024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clinical Infectious Diseases 2004; 39:1038-1046.
27. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Salas A, Merino E, Martinez-Lacasa J & del Rio L; ABCDE Study Team. Toxicity and efficacy of 3TC/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48-week results of a randomized open and multicenter trial (ABCDE Study), 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, USA. Abstract 716.
28. Gazzard BG, De Jesus E, Cahn P, Castillo H, Zhao H & Gordon D. Abacavir once daily plus lamivudine once daily in combination with efavirenz is well-tolerated and effective in the treatment of antiretroviral therapy naïve adults with HIV-1 infection (ZODIAC Study: CNA30021). 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, USA. Abstract H-1722b.
29. Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez AE & Shaefer MS. Abacavir/lamivudine in combination with efavirenz, amprenavir/ritonavir or stavudine: ESS40001 (CLASS) preliminary 48 week results. 14th International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract TuOrB1189.
30. Ferrer E, Santamarina E, Domingo P, Fumero E, Ribera E, Knobel H, Lopez JC, Barrios A & Podzamczer D. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/μl or less. AIDS 2004; 18:1727-1729.
31. Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC & Phillips AN. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. Journal of Infectious Diseases 1999; 180:530-533.
32. Raffi F, Reliquet V, Podzamczer D & Pollard RB. Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads. HIV Clinical Trials 2001; 2:317-322.
33. Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V & Gute P. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Medicine 2000; 1:162-163.
34. Knobel H, Miro JM, Mahillo B, Domingo P, Rivero A, Ribera E, Gonzalez J, Sanz J, Gonzalez A, Blanco JL, Boix V, Force L, Llibre JM, Dalmau D, Arroyo JA, De la Torre J, Rodríguez D, Montes ML, Arranz A & Sarasa M; GESIDA 26/02 Study Group. Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 study. Journal of Acquired Immune Deficiency Syndromes 2004; 37:1276-1281.
35. Launay O, Roudiere L, Boukli N, Dupont B, Prevoteau du Clary F, Patey O, David F, Lortholary O, Devidas A, Piketty C, Rey E, Urbinelli R, Allaert FA, Treluyer JM & Caumes E; Viramune-Zyrtec Study Group. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. Clinical Infectious Diseases 2004; 38:66-72.
36. Raffi F, Reliquet V, Ferre V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garre M, May T, Molina JM, Perre P, Raguin G, Rozenbaum W & Zucman D. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antiviral Therapy 2000; 5:267-272.
37. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, Barracchini A, De Longis P, Murri R, Tozzi V, Ammassari A, Rizzo MG, Ippolito G & De Luca A. Female sex and the use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15:1579-1581.
38. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick Jr HJ, Powderly WG & Mundy LM. Sex differences in nevirapine rash. Clinical Infectious Diseases 2001; 32:124-129.
39. Mazhude C, Jones S, Murad S, Taylor C & Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566-1568.
40. Dieterich DT, Robinson PA, Love J & Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clinical Infectious Diseases 2004; 38(Suppl 2):S80-S89.
41. Baylor MS & Johann-Liang R. Hepatotoxicity associated with nevirapine use. Journal of Acquired Immune Deficiency Syndromes 2004; 35:538-539.
42. Clotet B, van der Valk M, Negredo E & Reiss P. Impact of nevirapine on lipid metabolism. Journal of Acquired Immune Deficiency Syndromes 2003; 34(Suppl 1):S79-S84.
43. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO & Reiss P; Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15:2407-2414.
44. Servais J, Nkoghe D, Schmit JC, Arendt V, Robert I, Staub T, Moutschen M, Schneider F & Hemmer R. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 28:221-225.